Taspoglutide: Side Effects
Known side effects, contraindications, and interactions
๐TL;DR
- โข5 known side effects documented
- โข0 mild, 2 moderate, 3 severe
- โข3 contraindications listed
Compare side effects across multiple peptides โ
Side Effects Severity Chart
Reported in 53-59% of taspoglutide-treated patients in T-emerge trials, far exceeding rates seen with exenatide (35%) and other GLP-1 agonists. Severity and persistence contributed directly to program termination.
Reported in 33-37% of patients. Like nausea, the vomiting rate was substantially higher than comparator GLP-1 agonists and was a primary driver of treatment discontinuation.
Local reactions at the injection site including pain, erythema, nodule formation, and pruritus. Related to the zinc-depot formulation and local immune responses. More common than with other injectable GLP-1 agonists.
Systemic allergic reactions including urticaria, angioedema, and anaphylactoid reactions were reported at significantly higher rates than comparators. Associated with anti-taspoglutide antibody formation.
Anti-taspoglutide antibodies were detected in approximately 49% of treated patients. These antibodies were associated with injection-site reactions, systemic allergic events, and potentially reduced efficacy.
โContraindications
- โขDevelopment was discontinued; not available for clinical use
- โขKnown hypersensitivity to GLP-1 receptor agonists
- โขHistory of medullary thyroid carcinoma or MEN2 (class-wide GLP-1 agonist contraindication based on rodent studies)
โ ๏ธDrug Interactions
- โขInsulin and sulfonylureas: Increased hypoglycemia risk (GLP-1 agonist class effect)
- โขOral medications: Delayed gastric emptying may affect absorption of co-administered oral drugs
Community-Reported Side Effects
See which side effects community members report most frequently.
Based on 5+ community reports
View community protocolsSafety Overview#
Taspoglutide's safety profile in the T-emerge clinical trials was characterized by unacceptably high rates of gastrointestinal adverse events, injection-site reactions, immunogenicity, and systemic hypersensitivity reactions. These safety and tolerability issues directly caused the termination of the phase 3 program in September 2010 and precluded regulatory submission.
Gastrointestinal Adverse Events#
The most prominent safety issue was severe gastrointestinal toxicity. In the T-emerge 2 trial:
| Adverse Event | Taspoglutide 10 mg | Taspoglutide 20 mg | Exenatide 10 mcg BID |
|---|---|---|---|
| Nausea | 53% | 59% | 35% |
| Vomiting | 33% | 37% | 16% |
These rates are substantially higher than those observed with modern GLP-1 agonists. For comparison, semaglutide 2.4 mg (Wegovy) produces nausea in approximately 44% of patients, but at a much higher therapeutic dose and with greater efficacy. Taspoglutide's GI profile at its therapeutic doses was worse than any GLP-1 agonist that ultimately reached the market.
The severity and persistence of GI side effects contributed to high discontinuation rates, undermining the clinical utility of the drug's glycemic benefits.
Immunogenicity#
Anti-taspoglutide antibodies were detected in approximately 49% of patients in the T-emerge program. This rate was unprecedented for a GLP-1 receptor agonist and represented a critical safety liability:
- Antibody formation: Likely driven by the combination of non-native Aib residues and the zinc-depot formulation creating a persistent antigenic stimulus at the injection site
- Clinical consequences: Associated with injection-site reactions, systemic allergic events, and potentially reduced drug efficacy over time
- Comparison: Semaglutide and liraglutide have much lower immunogenicity rates, attributed to their albumin-binding approach rather than depot formulation
Injection-Site Reactions#
Local reactions at the injection site were significantly more common with taspoglutide than with comparator treatments. The zinc-based depot formulation created a persistent subcutaneous mass that acted as a focus for local immune responses. Reactions included:
- Pain and tenderness at the injection site
- Erythema and swelling
- Nodule formation
- Pruritus
Systemic Hypersensitivity#
Systemic allergic reactions, including urticaria, angioedema, and anaphylactoid events, were reported in the taspoglutide arms of T-emerge trials at rates not observed with comparator drugs. These reactions ranged from mild skin manifestations to serious events requiring medical intervention.
Comparison with Approved GLP-1 Agonists#
| Safety Parameter | Taspoglutide | Semaglutide (Wegovy) | Liraglutide (Saxenda) |
|---|---|---|---|
| Nausea | 53-59% | 44% | 39% |
| Vomiting | 33-37% | 24% | 15% |
| Injection-site reactions | High | 0.2-1% | 2-3% |
| Anti-drug antibodies | 49% | <1% | <1% |
| Systemic allergic reactions | Reported | Rare | Rare |
| Regulatory outcome | Terminated | Approved | Approved |
Safety Profile Context#
Taspoglutide belongs to the Metabolic category of research peptides. Understanding the side effect profile of Taspoglutide is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.
Reported Side Effects#
The following side effects have been documented in clinical studies of Taspoglutide. Side effect severity and frequency are based on available clinical data.
Nausea#
Severity: severe | Frequency: very-common
Reported in 53-59% of taspoglutide-treated patients in T-emerge trials, far exceeding rates seen with exenatide (35%) and other GLP-1 agonists. Severity and persistence contributed directly to program termination.
Vomiting#
Severity: severe | Frequency: very-common
Reported in 33-37% of patients. Like nausea, the vomiting rate was substantially higher than comparator GLP-1 agonists and was a primary driver of treatment discontinuation.
Injection-Site Reactions#
Severity: moderate | Frequency: very-common
Local reactions at the injection site including pain, erythema, nodule formation, and pruritus. Related to the zinc-depot formulation and local immune responses. More common than with other injectable GLP-1 agonists.
Systemic Hypersensitivity Reactions#
Severity: severe | Frequency: uncommon
Systemic allergic reactions including urticaria, angioedema, and anaphylactoid reactions were reported at significantly higher rates than comparators. Associated with anti-taspoglutide antibody formation.
Anti-Drug Antibody Formation#
Severity: moderate | Frequency: very-common
Anti-taspoglutide antibodies were detected in approximately 49% of treated patients. These antibodies were associated with injection-site reactions, systemic allergic events, and potentially reduced efficacy.
Contraindications#
The following contraindications have been identified for Taspoglutide based on available research and pharmacological considerations:
- Development was discontinued; not available for clinical use
- Known hypersensitivity to GLP-1 receptor agonists
- History of medullary thyroid carcinoma or MEN2 (class-wide GLP-1 agonist contraindication based on rodent studies)
Individuals with any of these conditions should not use Taspoglutide without consulting a qualified healthcare provider.
Drug Interactions#
The following potential drug interactions have been identified for Taspoglutide:
- Insulin and sulfonylureas: Increased hypoglycemia risk (GLP-1 agonist class effect)
- Oral medications: Delayed gastric emptying may affect absorption of co-administered oral drugs
Drug interaction studies for Taspoglutide remain limited. Researchers should exercise caution when combining Taspoglutide with other compounds and consult relevant pharmacological references.
Related Reading#
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Taspoglutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.